9-[2-(phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2586-2591

  Van Rompay, Koen K A ^a   Cherrington, Julie M ^b   Marthas, Marta L ^a   Berardi, Christopher J ^a   Mulato, Andrew S ^b   Spinner, Abbie ^a   Tarara, Ross P ^a   Canfield, Don R ^a   Telm, Stephan ^a   Bischofberger, Norbert ^b   Pedersen, Niels C ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GILEAD SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SUBCUTANEOUS DRUG ADMINISTRATION; VIREMIA; VIRUS RESISTANCE;

EID: 0343116840     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2586     Document Type: Article

References (34)

1. Amman, A. J. 1994. Human immunodeficiency virus infection/AIDS in children: the next decade. Pediatrics 93:930-935.
2. Böttiger, D., L. Ståhle, S.-L. Li, and B. Öberg. 1992. Long-term tolerance and efficacy of 3′-azido-thymidine and 3′-fluorothymidine treatment of asymptomatic monkeys infected with simian immunodeficiency virus. Antimicrob. Agents Chemother. 36:1770-1772.
3. Cheeseman, S. H., D. Havlir, M. M. McLaughlin, T. C. Greenough, J. L. Sullivan, D. Hall, S. E. Hattox, S. A. Spector, D. S. Stein, M. Myers, and D. D. Richman. 1995. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:141-151.
4. Cherrington, J. M., A. S. Mulato, M. D. Fuller, and M. S. Chen. 1996. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob. Agents Chemother. 40:2212-2216.
5. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
6. De Clercq, E. 1995. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:200-239.
7. Del Gobbo, V., A. Foli, J. Balzarini, E. De Clercq, E. Balestra, N. Villani, S. Marini, C. F. Perno, and R. Calio. 1991. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res. 16:65-75.
8. Foli, A., K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, X. Gu, J. M. Cherrington, H. Mitsuya, and R. Yarchoan. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res., in press.
9. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
10. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
11. Gu, Z., H. Salomon, J. M. Cherrington, A. S. Mulato, M. S. Chen, R. Yarchoan, A. Foli, K. M. Sogocio, and M. A. Wainberg. 1995. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 39:1888-1891.
12. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C.-M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
13. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
14. Kavlick, M. F., T. Shirasaka, E. Kojima, J. M. Pluda, F. J. Hui, R. Yarchoan, and H. Mitsuya. 1995. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antiviral Res. 28:133-146.
15. Lohman, B. L., J. Higgins, M. L. Marthas, P. A. Marx, and N. C. Pedersen. 1991. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J. Clin. Microbiol. 29:2187-2192.
16. Lohman, B. L., M. B. McChesney, C. J. Miller, E. McGowan, S. M. Joye, K. K. A. Van Rompay, E. Reay, L. Antipa, N. C. Pedersen, and M. L. Marthas. 1994. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68:7021-7029.
17. Marthas, M. L., K. K. A. Van Rompay, M. Otsyula, C. J. Miller, D. Canfield, N. C. Pedersen, and M. B. McChesney. 1995. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 69:4198-4205.
18. Miller, C. J., M. Marthas, J. Torten, N. J. Alexander, J. P. Moore, G. F. Doncel, and A. G. Hendrickx. 1994. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J. Virol. 68:6391-6400.
19. Myers, G., J. A. Berzofsky, B. Korber, R. F. Smith, and G. N. Pavlakis. 1991. Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory, Los Alamos, N.Mex.
20. Otova, B., Z. Zidek, C. Holy, I. Votruba, and D. Frankova. 1994. Immunomodulatory properties of 9-(2-phosphonomethoxyethyl)adenine (PMEA). Folia Biologica 40:185-192.
21. Otsyula, M. G., C. J. Miller, M. L. Marthas, K. K. A. Van Rompay, J. R. Collins, N. C. Pedersen, and M. B. McChesney. 1996. Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus. Pediatr. Res. 39:630-635.
22. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
23. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
24. Sutjipto, S., N. C. Pedersen, C. J. Miller, M. B. Gardner, C. V. Hanson, A. Gettie, M. Jennings, J. Higgins, and P. A. Marx. 1990. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J. Virol. 64:2290-2297.
25. Tsai, C.-C., K. E. Follis, T. W. Beck, A. Sabo, R. F. Grant, N. Bischofberger, and R. E. Benveniste. 1995. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl)adenine (PMPA). Science 270:1197-1199.
26. Tsai, C.-C., K. E. Follis, A. Sabo, R. Grant, and N. Bischofberger. 1995. Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J. Infect. Dis. 171: 1338-1343.
27. Van Rompay, K. K. A., J. L. Greenier, M. L. Marthas, M. G. Otsyula, R. P. Tarara, C. J. Miller, and N. C. Pedersen. Zidovudine-resistant simian immunodeficiency virus with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Submitted for publication.
28. Van Rompay, K. K. A., M. L. Marthas, R. A. Ramos, C. P. Mandell, E. K. McGowan, S. M. Joye, and N. C. Pedersen. 1992. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob. Agents Chemother. 36:2381-2386.
29. Van Rompay, K. K. A., M. Otsyula, M. L. Marthas, and N. C. Pedersen. 1994. Simian immunodeficiency virus infection of newborn and infant rhesus macaques: an animal model for testing antiretroviral drugs. Int. Antiviral News 2:5-6.
30. Van Rompay, K. K. A., M. G. Otsyula, M. L. Marthas, C. J. Miller, M. B. McChesney, and N. C. Pedersen. 1995. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob. Agents Chemother. 39:125-131.
31. Van Rompay, K. K. A., M. G. Otsyula, R. P. Tarara, D. R. Canfield, C. J. Berardi, M. B. McChesney, and M. Marthas. 1996. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J. Infect. Dis. 173:1327-1335.
32. Villani, N., R. Calio, E. Balestra, J. Balzarini, E. De Clercq, E. Fabrizi, C. F. Perno, and V. Del Gobbo. 1994. 9-(2-Phosphonylmethoxyethyl)adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system. Antiviral Res. 25:81-89.
33. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:117-122.
34. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsh, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.